It is anticipated that Step 4 will occur over a minimum of 4 weeks; however this may vary among participants based on their Step 3 dosing interval stage. Accumulated blood volumes and the timing between leukapheresis procedures will determine the length of time between each step. Participants completing this protocol (version 6.0), who respond initially in Step 3 will receive a total of 5200 mg of Vorinostat. Participant completing the study, who repeat Step 3, will receive a total of 6000 mg of Vorinostat. For reference, participants who completed the previous version (5.0) received a total of 10,000 mg of Vorinostat without clear evidence of any durable drug-associated toxicity thus far.